

170 Companies Longevity in UK

170 Companies / Longevity in UK

1. Abcodia	29. Braintrain 20:20	57. DrThom
2. Abzena plc	30. BrainWaveBank	58. Eagle Genomics
3. Adaptimmune	31. C4X Discovery	59. Earlham Institute
4. Aerobit Health	32. Cambridge Biolabs	60. EnteroBiotix
5. AHA Health	33. Cambridge Oncometrix	61. Epistem Holdings
6. Akari Therapeutics	34. CareRooms	62. eScent
7. Alcove	35. CareZapp	63. eTherapeutics
8. Ally Smart Care	36. Celixir	64. Evox Therapeutics
9. Altacor	37. Cell Guidance Systems	65. Freeline Therapeutics
10. AMO Pharma	38. Cell Medica	66. Genedrive Plc
11. Aparito	39. CellAge	67. Give & Take Care
12. Arcis Biotechnology	40. CellCap Technologies	68. Graphnet Health
13. Aridhia Informatics	41. CellCentric	69. GW Pharmaceuticals
14. Arrayjet	42. Celleron Therapeutics	70. Healx
15. ARUK-Arthritis Research UK	43. Cellesce	71. Hello Daisy
16. Astex	44. Cera	72. Heptares Therapeutics
17. Atlas Biomed Group	45. Chronos Therapeutics	73. Heterogeneous
18. Auriens	46. Cobra Biologics	74. Horizon Discovery
19. Autism Biotech	47. Cognition Kit	75. Howz
20. Autolus Limited	48. Collagen Solutions	76. hVIVO
21. Avalon AI	49. Complete Care	77. iamYiam
22. Avita Medical	50. CRISPR Therapeutics	78. IDIS
23. babylon health	51. CTRL Group	79. ImmuPharma
24. BenevolentAI	52. Curam	80. IntelliHep
25. Biogelx	53. Cytex	81. Invizius
26. Bioline	54. Definigen	82. Jellagen
27. BioMoti	55. Destiny Pharma	83. Kalgera
28. Blue Maestro	56. Diagnostic Healthcare	84. Kareinn

170 Companies / Longevity in UK

85. Kemuri	115. Oxford Biodynamics	145. Sernova
86. Kraydel	116. Oxford BioMedica	146. Sismic
87. Lab21	117. Oxford Gene Technology	147. SkyePharma (Acquired by Vectura)
88. Levcept	118. Oxford Genetics	148. Solentim
89. Lifeline 24	119. Oxstem	149. Sphere Fluidics
90. LIFNano Therapeutics	120. Patients Know Best	150. StoriiCare
91. LIFT BioSciences	121. Perfectus Biomed	151. Suisse Life Science Group plc
92. Memrica	122. Phico Therapeutics	152. Swift Molecular Diagnostics
93. Methuselah Health	123. Phoqus Pharmaceuticals	153. Synpromics Ltd
94. Michelson Diagnostics	124. PhoreMost	154. T7
95. Micrima	125. Physiomics	155. TC BioPharm
96. miiCARE	126. Plasticell	156. Theolytics
97. Minatx	127. PneumaCare	157. Tissue Regenix
98. Molecular Vision	128. Precision Medicines	158. Touch Bionics
99. Mologic	129. Premaita Health	159. Tunstall Healthcare Group
100. Monica Healthcare	130. Proteome Sciences	160. ukactive
101. Mursla	131. Proximagen	161. ValiRX
102. Nanokick Technologies	132. Psioxus Therapeutics	162. Verona Pharma
103. nanoTherics	133. Q Chip (Acquired by Midatech Pharma)	163. Vertex Pharmaceuticals
104. Nemaura Pharma	134. QuantuMDx Group	164. Vida
105. NeoPhore	135. Quethera	165. Videregen
106. NeRRe Therapeutics	136. ReMe	166. VirionHealth
107. Nightstar Therapeutics	137. ReNeuron Group	167. Virttu Biologics
108. Nuclera Nucleics	138. Rexgenero	168. Walk With Path
109. Open Bionics	139. Rightangled	169. Xenetic Biosciences
110. Open Inclusion	140. Rogue Resolutions	170. Zio Health
111. Optibiotix Health	141. Roslin Cells	
112. Orca Pharmaceuticals	142. SAGE Therapeutics	
113. Orchard Therapeutics	143. Scancell	
114. Orthogem	144. Sensio Air	

Abcodia



Abcodia is a clinical stage company engaged in the commercial development of novel, validated tests for the early detection of cancer. The Company's first product is the ROCA Test for the early detection of ovarian cancer, and it is also expanding its pipeline of early detection technologies for lung, colorectal and pancreatic cancer. Abcodia's offerings are based on expertise in measuring and modeling dynamic changes over time of serum-based biomarkers before cancer is clinically diagnosed.

It maintains exclusive commercial access to a biobank of 5 million samples donated from 200,000 individuals over a 10-year period and has its own CLIA-certified laboratory. Abcodia holds strategic collaborations with leading global organizations including Cancer Research UK, University College London and other academic and industry partners.

Website:	http://abcodia.com
Number of Employees:	1-10
Location:	London
Founded in:	2010
Sector:	Regenerative medicine
Total Funding Amount:	\$10.2M

Abzena plc



Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products, a growing area that requires specialist knowledge and expertise. The Group has a global customer base which includes the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.

The term “Abzena inside” is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.

Website:	http://abzena.com
Number of Employees:	101-250
Location:	Cambridge
Founded in:	2002
Sector:	Personalized medicine
Total Funding Amount:	£40M

Adaptimmune



Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Stock Symbol: NASDAQ:ADA

Website:	http://adaptimmune.com
Number of Employees:	51-100
Location:	Oxton
Founded in:	2008
Sector:	Preventive medicine
Total Funding Amount:	\$149.5M

Aerobit Health



With 2/3rds of asthma deaths being preventable and the majority of severe asthma symptoms able to be significantly reduced, Aerobit sees creating tools to simplify the adherence and tracking of treatment as the biggest opportunity for improvement in the marketplace. Adherence with doctor-recommended treatment programs has long been recognized as a leading cause of unachieved outcomes. They see the upcoming revolution in digital health care as the turning point in delivering positive outcomes for UK asthma sufferers. They know that controlled asthma imposes far less of an economic burden than non-controlled asthma. Their strategies are focused towards improving adherence to doctor-recommended treatments.

Website:	http://aerobithealth.com
Number of Employees:	1-10
Location:	United Kingdom
Founded in:	N/A
Sector:	Preventive medicine

AHA Health



AHA goes beyond the ability to predict Health Risks and provides the ability to do something about it. Amazing technology for Patient Care that improves quality of care and drive the cost of care down.

- AHA Health helps you to gather personal health information whether you are at home or work through questionnaires, medical devices, wearables and data from healthcare providers into a Single Personal Health Record.
- AHA Health's health risk monitoring engine can analyse trends and pick up abnormalities in near real time based on clinically validated algorithms as well as personalised monitoring parameters set by the Doctors.
- AHA Health's Intervention support system can alert you, your Carer and Doctor of any issues and empower them to provide proactive healthcare. AHAHealth helps doctors to diagnose diseases before its too late.
- AHA Health's machine learning platform can identify Patterns and clusters to create unique Digital health therapeutics or algorithmic models that will change the way health care is provided in future. It helps Doctors provide good quality of care.

Website:	https://ahahealth.io/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	Personalized medicine

Akari Therapeutics



Akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. Akari's lead drug, Coversin is a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (also known as the membrane attack complex or MAC). C5 inhibition is growing in importance in a range of rare autoimmune diseases related to dysregulation of the complement component of the immune system, including paroxysmal nocturnal hemoglobinuria (PNH), atypical Hemolytic Uremic Syndrome (aHUS), and Guillain Barré syndrome (GBS).

Stock Symbol NASDAQ:AKTX

Website:	http://akaritx.com/
Number of Employees:	11-50
Location:	London
Founded in:	2005
Sector:	Preventive medicine
Total Funding Amount:	\$87.5M

Alcove



Alcove was formed in 2014 with the aim to pioneer independent living for older and disabled adults. Revolutionising care and support by leveraging the power of today's consumer technology to empower users and provide care givers with better tools. Mostly, their customers just get on with their lives as normal - they don't have to do anything differently. If they do, they have locked down all their devices so they are super simple to use.

Website:	http://www.youralcove.com
Number of Employees:	11-50
Location:	London
Founded in:	2014
Sector:	AgeTech

Ally Smart Care



Ally Smart Care can help with early detection and treatment of falls, chest infections, UTIs and depression.

Website:	https://ally.is/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	Preventive medicine

Altacor (Acquired by Esperante Ventures)



Altacor develops and brings to market specialist ophthalmic products designed for the needs of both ophthalmologists and patients.

From its headquarters in Cambridge UK, Altacor brings together skills in drug development with in-depth market knowledge and an understanding of the European regulatory environment, to create a portfolio of high quality, differentiated prescription medicines that set new standards in the sector.

Altacor's pipeline includes products for dry-eye, glaucoma, glaucoma surgery and ocular surgery.

Website:	http://www.altacor-pharma.com/
Number of Employees:	11-50
Location:	Berkshire
Founded in:	2005
Sector:	Regenerative medicine
Total Funding Amount:	£1.9M

AMO Pharma



AMO Pharma is dedicated to making a positive difference for people affected by serious and debilitating diseases, particularly rare or orphan diseases. To do this, we first work to understand the areas of unmet need and the experience of living with any disease we are targeting. We then use our extensive experience in drug development to identify and advance therapies that can significantly improve clinical outcomes while offering the strongest opportunities for approval. With drugs designed to reduce disease burden, slow disease progression or reduce many or all symptoms of a disease, our goal is to give patients an opportunity for improved health and quality of life. Our passion for drug development is strengthened and inspired by many personal connections to the rare disease community held by members of our senior team.

Website:	http://www.amo-pharma.com/
Number of Employees:	N/A
Location:	Wonersh
Founded in:	N/A
Sector:	Regenerative medicine
Total Funding Amount:	\$25M

aparito They provide wearable devices and disease-specific mobile apps to provide remote patient monitoring outside of the hospital environment.

This delivers meaningful, relevant, and real-time data between patients and clinicians in a way that actively supports and enhances diagnosis, treatment and drug development. By embracing digital health technology.

They connect patients to doctors - and to parents/ carers – via remote monitoring to support better patient outcomes, improve understanding of disease, and clinical trial outcomes.

Website:	https://www.aparito.com/
Number of Employees:	1-10
Location:	United Kingdom
Founded in:	2015
Sector:	Personalized medicine
Total Funding Amount:	£15K

Arcis Biotechnology



Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly and conveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles.

Website:	http://www.arcisbio.com/
Number of Employees:	1-10
Location:	Warrington
Founded in:	2009
Sector:	Personalized medicine
Total Funding Amount:	£5.3M

Aridhia Informatics



Aridhia provides world leading biomedical informatics and analytic solutions to support stratified medicine and translational research, which will enhance understanding, diagnosis, prevention and treatment of chronic diseases. Aridhia believes that the integration and application of patient, clinical and genomic data represents a powerful opportunity to support clinical care across healthcare sectors, provide patients with the ability to take a more active role in their own care and provide information at a population level about disease trends, risk factors, impact of treatment and informed public health programmes. Working in close collaboration with experts in a clinical faculty model, Aridhia's multidisciplinary team provides a unique combination of expertise to address one of the world's most pressing health problems.

Website:	http://www.aridhia.com
Number of Employees:	51-100
Location:	Edinburgh
Founded in:	2008
Sector:	Personalized medicine
Total Funding Amount:	£1.1M

Arrayjet Ltd was established in 2000 with private equity from the Archangel Investors Ltd and the Scottish Government. The company developed and patented an inkjet technology to print biological samples onto solid substrates to create screening tools called microarrays. Arrayjet have been at the forefront of this field since commercialisation in 2006 and have a broad customer-base across 27 countries. Arrayjet has strong brand presence and a respected reputation for high-throughput inkjet printing systems, dependable customer service and assay development expertise. Arrayjet was originally an instrument business but began developing a contract service arm in 2010. In 2011 we launched Arrayjet Advance™ to offer a range of out-sourced services for assay development, printing and contract manufacturing. In 2016 we added Arrayjet Expertise™ to offer services for consultancy, project management and training.

Website:	https://www.arrayjet.co.uk/
Number of Employees:	11-50
Location:	Edinburgh
Founded in:	2000
Sector:	Personalized medicine



Everything we do is driven by knowledge to positively impact on what matters to people with arthritis.

Our long term commitment is to:

- **prevent** the onset of arthritis
- develop a **cure** for arthritis
- **transform** the lives of those with arthritis.

Too many people live with the pain, isolation and fatigue arthritis causes. This has to stop.

Arthritis Research UK has merged with Arthritis Care so that we can address this huge unmet need and do more for, and with, people with arthritis.

Website:	http://www.arthritisresearchuk.org
Number of Employees:	101-250
Location:	N/A
Founded in:	N/A
Sector:	Personalized medicine

Astex (Acquired by SuperGen)



Astex is a UK-based biotechnology company that discovers and develops novel small molecule therapeutics. Using its pioneering fragment-based drug discovery platform, Pyramida, Astex has built a pipeline of molecularly-targeted oncology drugs, of which three are currently being tested in clinical trials with others in discovery and pre-clinical development.

In addition to its proprietary research programs, Astex™s productivity in lead discovery has been endorsed through numerous partnerships with major pharmaceutical companies, including AstraZeneca, GlaxoSmithKline, Johnson & Johnson and Novartis.

Website:	https://astx.com/
Number of Employees:	51-100
Location:	Cambridge
Founded in:	1999
Sector:	Personalized medicine

Atlas Biomed Group



Atlas Biomed is a personalised health company, applying the latest genetic technologies to help you navigate towards your potential. To achieve this, Atlas has two tests available in the UK: the Atlas DNA Test and the Atlas Microbiome Test. Both tests feed into the Atlas platform, which allows you to take control of your health through actionable, personalised recommendations.

Website:	https://atlasbiomed.com/uk
Number of Employees:	51-100
Location:	London
Founded in:	2016
Sector:	Personalized medicine

Auriens



Some people use the phrase ‘over the hill’. At Auriens that just means picking up speed.

Through their beautifully designed properties, world-class services and exceptional healthcare provision, Auriens is dedicated to challenging and subverting the norms of post-retirement (later) living.

They see the advancing years as something to celebrate, and they value agefulness as they do intelligence, attitude, style and sophistication.

At Auriens, their mission is to provide inclusive, comprehensive, centrally located places to live later life to the full. That means the catering is exceptional, the Club and restaurant are stylish places to congregate, and the spa, therapy suites and library are all a joy to linger in. Every requirement, large or small, will be effortlessly satisfied to premium hotel standards and beyond.

Here age is more than just a number – it’s a rite of passage to a lifestyle that is as entertaining and enjoyable as it is comfortable.

Website:	https://www.auriens.com/
Number of Employees:	2-10
Location:	London
Founded in:	N/A
Sector:	AgeTech

Autism Biotech



Autism Biotech Ltd has a ground-breaking product: ASDtect, the world's first diagnostic test for early and reliable detection of autism spectrum disorder (ASD). Based on two fully owned and granted patents for peptide biomarkers for autism, ASDtect targets a huge and untapped market.

Website:	https://www.autism-biotech.com/
Number of Employees:	1-10
Location:	Belfast
Founded in:	N/A
Sector:	Preventive medicine

Autolus Limited




Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognise cancer cells, break down their defence mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors.

Stock Symbol: NASDAQ:AUTL

Website:	http://www.autolus.com/
Number of Employees:	11-50
Location:	London
Founded in:	2014
Sector:	Personalized medicine
Total Funding Amount:	\$181.7M

Avalon AI



Avalon AI builds Deep Learning-based Computer Aided Diagnosis tools to facilitate the detection of brain degenerative diseases like Alzheimer's and enable better patient stratification in clinical trials.

We use Machine learning to automatically derive accurate brain features (e.g. the volume of the hippocampus) from brain scans and compare them to a normative population. We also provide handy 2D and 3D visualisations of brain features. This not only saves time to neuroradiologists but also empowers them to make highly accurate reports, by using the latest techniques and findings in neurosciences. We are currently running trials with select clinics in India, Pakistan and Ukraine.

Website:	http://avalonai.strikingly.com
Number of Employees:	51-100
Location:	London
Founded in:	2015
Sector:	Preventive medicine

Avita Medical



Avita also has the opportunity to receive up to \$37 million upon execution of specific contract options to further support clinical studies and post-market surveillance that could be potentially required by the FDA to expand the device to the pediatric population, the company said.

Stock Symbol ASX:AVH

Website:	http://www.avitamedical.com/
Number of Employees:	11-50
Location:	Wimbledon
Founded in:	1999
Sector:	Regenerative medicine
Total Funding Amount:	\$28.6M

Babylon Health



babylon delivers high quality healthcare via your mobile phone. babylon employs only the very best doctors and provides them with rigorous industry-leading training.

During video visits doctors listen and look carefully to diagnose you or your family member and then write prescriptions or refer you to a specialist if required. Patients rate each visit to ensure quality.

Their mission is the total re-invention of healthcare. They believe technology can be used to give everyone, everywhere, affordable quality medical care. That's why they are creating everyone's own personal health service.

Website:	https://www.babylonhealth.com/
Number of Employees:	251-500
Location:	United Kingdom
Founded in:	2013
Sector:	Preventive medicine
Total Funding Amount:	\$85M

BenevolentAI is one of the largest private AI companies in the world and the global leader in the development and application of AI for scientific innovation.

The company is applying artificial intelligence to develop new medicines for hard to treat diseases. It is the first fully integrated AI company with pharmaceutical discovery and clinical development capabilities. BenevolentAI's advanced technology is disrupting the pharmaceutical industry by lowering costs, decreasing failure rates and increasing the speed at which medicines are delivered to patients.

BenevolentAI currently employs 165 people who work in a unique, cross functional environment that incorporates leading edge data scientists, computer scientists, mathematicians and drug development R&D scientists working side by side. The company is headquartered in London with further offices in New York and Belgium. BenevolentAI's research facility is located in Babraham Science Park, Cambridge (UK).

Website:	http://benevolent.ai/
Number of Employees:	51-100
Location:	London
Founded in:	2013
Sector:	AgeTech
Total Funding Amount:	\$202M



Biogelx is a biomaterials company which designs and supplies peptide hydrogels for cell culture, precisely tuned to the requirements of the cell. These products have applications in fundamental cell research, toxicology/drug development and may ultimately be translated to cell therapy/regenerative medicine. The chemical and physical properties of the hydrogels match the characteristics experienced by cells within tissues, thus enabling the study and manipulation of cells in a realistic 3D environment which is simple, fully defined and tuneable.

The Company's patented hydrogel products are currently selling in the US, Europe and Asia.

The product's unique cell-matching capabilities clearly provide academic users, medical researchers and pharmaceutical companies with a serious alternative to competing 3D cell culture products.

Website:	http://biogelx.com/
Number of Employees:	1-10
Location:	Newhouse
Founded in:	2012
Sector:	Personalized medicine

Bioline



Founded in 1992 and headquartered in London, UK, Bioline is an evolving international company and our mission is to provide customers with a range of products which are fast and easy to use, guaranteed to work and developed by scientists who understand what our customers are trying to achieve so they can focus on their scientific goals. At Bioline, we constantly strive to improve and to deliver high quality products which are the result of our strong commitment and investment in science. Bioline, wholly owned by Meridian Bioscience Inc. (Nasdaq: VIVO), operates as one multi-cultural global team with strong values.

Website:	https://www.bioline.com/
Number of Employees:	251-500
Location:	London
Founded in:	1992
Sector:	Personalized medicine
Total Funding Amount:	\$903K

One in three of us will get cancer and increases in life expectancy indices will exacerbate this statistic in the future. Most current chemotherapeutics have devastating side effects including hair loss, nausea, weakened immunity and fatigue to name but a few.

BioMoti exists to transform the treatment of cancer patients by doing things differently. BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to dramatically increase efficacy whilst reducing side effects.

Oncojans™ are a new class of therapeutic microparticles that target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The Oncojan™ platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.

Website:	http://www.biomoti.com
Number of Employees:	1-10
Location:	London
Founded in:	2009
Sector:	Preventive medicine
Total Funding Amount:	£75K

Blue Maestro



Blue Maestro is a leading designer and developer of connected products and solutions, from consumer devices through to their work with NHS England on the next generation of medicine adherence sensors. They have a number of innovative products and solutions under development, several that are patent pending. Meet some of Blue Maestro's management team below.

Website:	https://www.bluemaestro.com
Number of Employees:	1-10
Location:	Weybridge
Founded in:	2012
Sector:	AgeTech
Total Funding Amount:	\$410K

Braintrain



Braintrain20:20 is a groundbreaking cognitive science development company. Our first product, SleepCogni, is a proprietary pioneering electronic sleep aid device which winds you down to a sleep-ready state using audio, visual and tactile stimuli. We use personal bio-algorithmic data to drive the products responses, reducing the time taken to get to sleep and improving overall quality.

Website:	http://braintrain2020.com/
Number of Employees:	11-50
Location:	Sheffield
Founded in:	2015
Sector:	Regenerative medicine
Total Funding Amount:	£485K

BrainWaveBank



BrainWaveBank's neuroscience platform measures cognitive performance by monitoring brainwave activity while playing fun, engaging mobile games that test specific aspects of your cognitive health. By playing the games for just a few minutes a day, several times a week, a record of your cognitive health is created. Analytics allow you to understand how your performance varies over time and how it is affected by sleep, diet, and exercise, informing you how to make changes to your lifestyle that can optimise your cognitive health and help delay onset of age-related or illness-related cognitive decline.

BrainWaveBank was founded by Ronan Cunningham, Brian Murphy, Siggi Saevarsson and Urs Streidl in January 2015. It is based in Belfast, Northern Ireland.

Website:	http://www.brainwavebank.com
Number of Employees:	1-10
Location:	Belfast
Founded in:	2015
Sector:	Personalized medicine
Total Funding Amount:	£1M

C4X Discovery



C4X Discovery aims to become the world's most productive drug discovery and development company by exploiting cutting-edge technologies to design and create best-in-class drug candidates. The Company has two proprietary and synergistic software platforms "Taxonomy3®" and "Conformetrix" that provide a significant competitive advantage when combined with an experienced management team. "Taxonomy3®" is a human genetics analysis platform that utilises a unique mathematical approach to discovery and validation of drug targets for the treatment of a variety of diseases. "Conformetrix" determines the 3D shape of drug molecules from experimental in vitro data that enables the rapid design and discovery of novel and potent drugs for diseases with high unmet medical need across broad therapeutic areas. C4XD's drug discovery engine was further strengthened by the acquisition of technologies from Molplex Ltd, in 2016, which included a software-based system which combines chemoinformatics, computational chemistry and artificial intelligence to optimise the drug discovery process. We have a hybrid business model of wholly-owned programmes and partnerships with pharma, biotech and academics.

Website:	https://www.c4xdiscovery.com/
Number of Employees:	N/A
Location:	Manchester
Founded in:	2007
Sector:	Personalized medicine

Cambridge Biolabs



Millions of people all around the world use ineffective or unsuitable cosmetics every day because the off-the-shelf products currently available on the global cosmetic market do not correspond to the complex set of needs of every individual. This leads to inadvertent negligence and wrong choices due to lack of optimal solution. Skin condition deterioration ensues.

To overcome this we are developing Personal Cosmetic System consisting of more possible personalised formulations than people on Earth. After individual skin diagnosis aided by advanced software and hardware the optimal formula is worked out and created uniquely for the patient in question.

Our formulations are designed to deliver. Each personalised formula boasts a large number of active ingredients (20-40) thus providing unprecedented level of skin health benefits as compared to the 2-3 active ingredients present in most cosmetics currently available on the market.

Thanks to its uniqueness Personal Cosmetic System makes sure that nobody neglects some of his or her skin needs due to lack of choice and knowledge. It also ensures that, based on individual tolerance, unwanted substances be avoided and optimal results achieved.

Website:	http://www.cambridge-biolabs.com
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2016
Sector:	Personalized medicine

Cambridge Oncometrix



Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer. A condition that is likely to affect 1 in 8 men at some stage of their lives.

Cambridge Oncometrix is developing a non-invasive test that will allow men to check the health of their prostate regularly. A simplified version of the test will be available for home use. A more advanced version will be used in medical institutions.

This test will be capable of accurately detecting aggressive forms of prostate cancer at the early stages of its development.

Website:	http://www.camonx.org/
Number of Employees:	1-10
Location:	Haverhill
Founded in:	2012
Sector:	Preventive medicine

CareRooms



We are working with homeowners in your community to provide safe, comfortable CareRooms for convalescence as an alternative to a long hospital stay, to avoid admission into hospital and for short respite breaks. We transform unused spare rooms with our connected healthcare platform, create networks of trained Hosts and put quality of life at the heart of all we do.

Website:	https://carerooms.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	Personalized medicine

CareZapp



For people who need care at home, whether as a result of ageing, disability or other needs - CareZapp helps connect providers and caring people, providing better insights through smart technologies to enable more effective and positive outcomes.

The CareZapp platform aggregates real-time data from best-of-breed in-home sensors and digital devices, utilised within our applications and analytics to provide meaningful notifications, alerts and better insights on a 24/7 year-round basis.

Our companion apps help to drive engagement within a holistic support network of caring professionals, family, friends, neighbours and community supports for better collaboration, coordination and self-management.

Website:	http://www.carezapp.com/
Number of Employees:	1-10
Location:	Dublin
Founded in:	2014
Sector:	AgeTech



The team of world-class scientists and biotechnology leadership is devoted to discovering breakthrough medicines that change the standard of medical care for patients. Sir Martin Evans, Nobel Laureate, and Ajan Reginald, former Global Head of Emerging Technologies at Roche, originally founded the company under the name Cell Therapy Ltd (CTL) in 2009 which was rebranded as Celixir in 2016.

Website:	http://www.celixir.com/
Number of Employees:	11-50
Location:	Cardiff
Founded in:	2009
Sector:	Regenerative medicine

Cell Guidance Systems



Cell Guidance Systems commercializes innovative technologies to accelerate and enable stem cell science. We are focussing on (1) the culture of human pluripotent stem cells and (2) the development of highly active, potentiated growth factors. (3) the commercialization of SINEUP technology. SINEUP allows upregulation of protein expression from target genes using an lncRNA transfected into the target cell. Cell Guidance Systems has offices in Cambridge, UK and San Diego, California.

Website:	http://www.cellgs.com
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2010
Sector:	Regenerative medicine
Total Funding Amount:	£620.9K

Cell Medica



Cell Medica is a cell therapy company working on new techniques to cure human diseases based upon a treatment method called cellular immunotherapy. This technique involves harnessing and enhancing the power of the human immune system to fight disease.

Based on a number of academic studies, there is strong evidence that cellular immunotherapy can be used in a safe and effective manner to treat diseases ranging from infections to cancer.

Cell Medica is both an R&D company developing new forms of cell therapies and a cell production/processing company providing clinical-grade cell formulations to hospitals for the treatment of patients.

Website:	http://www.cellmedica.co.uk
Number of Employees:	11-50
Location:	London
Founded in:	2006
Sector:	Personalized medicine
Total Funding Amount:	\$191.8M

We dream of a world where all people can enjoy their 80s as much as they enjoyed their 20s. A world where people no longer suffer from age-related diseases. A world where we are all given more time to spend with our loved ones.

Website:	http://www.cellage.org/
Number of Employees:	11-50
Location:	Glasgow
Founded in:	2016
Sector:	Personalized medicine

CellCap Technologies Limited was formed in 2012 to exploit their research over the last 2 years in cell separation technologies.

CellCap is using the company's unique approach to cell capture to develop simple consumables for the Life Sciences research sector.

Website:	http://www.cell-capture.com
Number of Employees:	1-10
Location:	Bacup
Founded in:	2012
Sector:	Regenerative medicine
Total Funding Amount:	£75K

CellCentric's primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such as Xtandi and Zytiga.

The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Website:	http://cellcentric.com
Number of Employees:	N/A
Location:	Cambridge
Founded in:	2003
Sector:	Regenerative medicine
Total Funding Amount:	\$32.6M

Celleron Therapeutics




Celleron is building a global oncology company focussed on the clinical development of new and innovative therapies to treat cancer. Celleron's vision is that the future of cancer therapy lies in the ability to match patients to treatments that are tailored to their tumours – effectively selecting the right drug, at the right dose, for the right patient.

Celleron is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. The Company's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified.

Website:	http://cellerontherapeutics.com/
Number of Employees:	N/A
Location:	Abingdon
Founded in:	2005
Sector:	Preventive medicine

Cellesce



Cellesce Ltd is a biochemical engineering company based in Cardiff in the UK. Cellesce's expertise is in cell expansion which is currently focused on organoids.

Website:	http://www.cellesce.com/
Number of Employees:	1-10
Location:	Malmesbury
Founded in:	2013
Sector:	Regenerative medicine

Launched in November 2016, Cera is a homecare provider that uses digital and artificial intelligence to transform social care. It was co-founded by Dr. Ben Maruthappu and Marek Sacha. Through Cera's matching algorithm and automated scheduling systems, Cera is able respond to enquiries within the hour, and in 96% of cases start care on the same day when requested. Cera has significantly lower overheads compared to traditional care companies, allowing the company to pay carers up to 50% higher than the industry average, while still offering affordable rates for customers. Cera has received a number of awards including the Most Outstanding Digital Health Innovation of the Year, the LaingBuisson Dementia Care Award, the Best London Home Care Company at the Social Care Awards 2018, Disruptive Leader of the Year and Britain's Health Startup of the Year. It is a member of the PUBLIC GovStart programme.

Website:	http://ceracare.co.uk
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	Personalized medicine
Total Funding Amount:	\$21.1M

Chronos Therapeutics



Chronos Therapeutics' drug development scheme focuses in two main areas:

- Repositioning FDA approved drugs.
- Screening, discovery and development of novel proprietary drug candidates.

Current Targets

- Diseases of Ageing: Osteoporosis, Cancer and Sarcopenia.
- Neurodegenerative Diseases: Parkinson's Disease, Alzheimer's Disease, ALS and Orphan Synucleopathies.

Chronos Therapeutics' research is successfully advancing from pre-clinical stages of development for age-related disease treatments to clinical development.

Chronos' pioneering drug discovery and development platform the Chronoscreen has enabled the company to quickly gain proprietary positions in the regulation of cellular chronological lifespan.

Some of the most exciting and effective therapeutic approaches of the future will utilize our understanding of the biological programming of life-span and ageing that take place in every cell of our body. Harnessing this knowledge will lead to novel treatments for age related diseases such as Alzheimer's Disease, Diabetes, Cancer and Osteoporosis.

Website:	http://chronostherapeutics.com
Number of Employees:	11-50
Location:	Oxford
Founded in:	2009
Sector:	AgeTech
Total Funding Amount:	£8M

Cobra Biologics



Cobra Biologics is a leading international contract manufacturing organisation (CMO) providing biologics and pharmaceuticals for pre-clinical, clinical and commercial supply.

Cobra has three GMP approved facilities in Sweden and the UK, each with expertise tailored to serving our customers around the world. We offer a broad range of integrated and stand-alone contract development and manufacturing services for clinical trials and the commercial market.

As a trusted provider and a key partner in the drug development and commercialisation process, we take pride in our manufacturing excellence and comprehensive range of services to the pharmaceutical and biotech industries.

Cobra is a Contract Manufacturing Organisation (CMO) supporting the global life sciences industry in the development and manufacture of monoclonal antibodies (mAb), recombinant proteins, DNA, viruses, phage and cell line derived products and pharmaceuticals for clinical trials and commercial supply.

Over 15 years of track record in producing biologics and pharmaceuticals for use in pre-clinical to Phase III clinical trials and commercial supply has given our people a unique knowledge base as both manufacturer and also as service providers for the global life sciences market.

Website:	http://www.cobrabio.com
Number of Employees:	501-1000
Location:	Keele
Founded in:	1992
Sector:	Regenerative medicine
Total Funding Amount:	£2.6M

Cognition Kit



Cognition Kit is a platform that will enable doctors, scientists and the public to better understand and manage day-to-day brain health.

Website:	http://www.cognitionkit.com/
Number of Employees:	n/a
Location:	n/a
Founded in:	n/a
Sector:	AgeTech

Collagen Solutions



Collagen Solutions Plc is a global provider of medical grade collagen formulations and components for use in regenerative medicine, medical devices and in-vitro diagnostics.

Our capabilities include the provision of native, soluble and powdered collagen formulations and expertise in the development and contract manufacture of collagen components for use as tissue scaffolds and medical devices.

Collagen Solutions' unique offering extends beyond material supply and contract services as our highly skilled staff support customers through various stages of development and regulatory approval, establishing long-term commercial relationships.

Website:	http://collagensolutions.com
Number of Employees:	11-50
Location:	London
Founded in:	2012
Sector:	Regenerative medicine
Total Funding Amount:	£18M

Complete Care



Complete Care provides high acuity care at home to around 150 individuals with on-going complex clinical healthcare needs. The business employs around 650 personal care assistants (including registered nurses). This acquisition will complement Mitie's existing domiciliary care operations in England and Wales, which are primarily operated through MiHomecare.

Website:	http://www.completecure.co.uk/
Number of Employees:	N/A
Location:	Telford
Founded in:	1996
Sector:	AgeTech

CRISPR Therapeutics



CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics' vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Website:	http://crisprtx.com/
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2013
Sector:	Regenerative medicine
Total Funding Amount:	£127M

CTRL Group



Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people's health. We create products and services that are effective, engaging and safe.

Website:	https://www.ctrl-group.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	Personalized medicine

We at Curam believe that you are the best person to choose your carer or personal assistant – our platform allows you to do this safely, easily and effectively. We have a 12.5% administration charge compared to a typical ISF support provider who will charge over 25% or a traditional agency that will charge up to 50% of the cost of care.

Website:	https://www.curamcare.com/
Number of Employees:	N/A
Location:	UK
Founded in:	2018
Sector:	Personalized medicine

Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer's Disease in the very early stages. Alzheimer's Disease affects over 26 million people world-wide and is a growing condition as people live longer. There is currently no cure for Alzheimer's Disease, but there are large international initiatives underway to find treatments with many drugs in clinical development. Cytox are commercially launching their tests in conjunction with Affymetrix (part of Thermo Fisher Scientific) to support Pharmaceutical and Biotechnology companies developing novel therapeutics.

Website:	http://cytoxgroup.com
Number of Employees:	1-10
Location:	Manchester
Founded in:	2004
Sector:	Preventive medicine
Total Funding Amount:	£10.3M

Definigen



DefiniGEN was founded in April 2012 to industrialize the OptiDIFF stem cell production platform developed at the University of Cambridge, UK.

The company has world-leading expertise in the area of iPSC production and metabolic disease modelling. The application of these technologies in drug discovery provides pharmaceutical companies with more predictive in vitro cell products enabling the development of safer and more effective treatments. In addition the technology platform utilises fully defined and humanized conditions required for the development of regenerative medicine cellular therapies.

DefiniGEN builds on intellectual property and knowledge resident at the University of Cambridge Regenerative Medicine Department at Addenbrooke's Hospital and in addition has in-licensed the Yamanka induced pluripotent stem cell IP portfolio from iPS Academia Japan Inc.

Website:	http://definigen.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2012
Sector:	Regenerative medicine
Total Funding Amount:	£5.1M

Destiny Pharma



Destiny Pharma is an innovative pharmaceutical company dedicated to the development of novel antimicrobial products.

Our XF series of compounds have a mechanism of action that is fundamentally different from all existing antibiotics. As the likelihood of resistance developing is very remote, they offer potential advantages in controlling the drug-resistant bacteria that are at the centre of a global healthcare crisis.

Website:	http://www.destinypharma.com
Number of Employees:	1-10
Location:	Brighton
Founded in:	1996
Sector:	Preventive medicine
Total Funding Amount:	\$37M

Diagnostic Healthcare



Diagnostic Healthcare Ltd, an Altrincham, UK-based diagnostic imaging company. Led by Liat Karni, managing director, and Michael Ringart, chairman, Diagnostic Healthcare has a network of centres and mobile units across the UK providing MRI scans, obstetric ultrasound, bone density scans (DEXA scan), cardiac testing, health screening and reporting services.

The company offers end-to-end integrated solutions, either as mobile services or located within hospitals, GP surgeries or dedicated community sites.

Website:	http://www.diagnostichealthcareltd.com
Number of Employees:	11-50
Location:	Altrincham
Founded in:	2004
Sector:	Preventive medicine
Total Funding Amount:	£1M

DrThom teamed up with their parent company LloydsPharmacy. LloydsPharmacy Online Doctor offers a wider range of treatment options, available at cheaper prices. Our NHS accredited doctors have helped treat over 1,000,000 patients in the UK for a variety of conditions.

Website:	http://www.drthom.com
Number of Employees:	N/A
Location:	London
Founded in:	2002
Sector:	Personalized medicine

Eagle Genomics



Eagle Genomics is an enterprise software solutions company whose products enable the management, orchestration and exploitation of genomics and other life sciences data. We help Life Science companies get the maximum value from their R&D data and we are delivering the information architecture for the genomics era. Our suite of software products radically reduces cost and time to complete research, enabling drastic productivity improvements.

Our architecture translates data sets into data assets, redefining the current paradigm in the industry, enabling the objective measurement of the value of digital assets and providing clarity on “return on information”. Our mix of expertise in biology, bioinformatics, data science and enterprise-class software engineering is unique in the field and has been applied over the last decade to solve our customers’ challenges in areas as diverse as drug development, personal hygiene and plant breeding.

With global customers in the pharmaceuticals, fast moving consumer goods and agri-tech industries we understand the common challenges facing these industries in the handling of ever growing data and information resources.

Website:	http://www.eaglegenomics.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2008
Sector:	Regenerative medicine
Total Funding Amount:	\$7.7M

The Earlham Institute (EI) is a research institute focused on exploring living systems by applying computational science and biotechnology to answer ambitious biological questions and generate enabling resources.

Website:	http://www.earlham.ac.uk
Number of Employees:	N/A
Location:	Norwich
Founded in:	2009
Sector:	Personalized medicine

EnteroBiotix



EnteroBiotix, a privately held Scottish biotechnology company focused on using the body's own microorganisms to prevent and treat disease, has raised £500,000 in an oversubscribed seed round of investment. The financing was led by Equity Gap and supported by the Scottish Investment Bank, the investment arm of Scottish Enterprise.

Website:	http://enterobiotix.com
Number of Employees:	N/A
Location:	United Kingdom
Founded in:	2017
Sector:	Preventive medicine
Total Funding Amount:	£500K

Epistem Holdings



Epistem's specialist contract research services provide valuable support to drug discovery and development pipelines. Epistem's experienced and skilled technical team are dedicated to working with you to provide custom protocols and a personalised service of the highest standard.

Website:	http://epistemservices.com
Number of Employees:	51-100
Location:	Manchester
Founded in:	2000
Sector:	Personalized medicine
Total Funding Amount:	£2.5M



eScent® is a highly scalable platform technology that emits microdoses of mood-enhancing aromas at the right time, in the right place, depending on context

eScent® Contextual Technology for innovations in sensing and dispensing fragrances for digital healthcare, wellbeing, fashion, fragrance, retail applications.

Founded by Dr Jenny Tillotson, Winston Churchill Fellow and Visiting Scholar at the Institute of Biotechnology, University of Cambridge.

Website:	http://www.escent.ai/
Number of Employees:	N/A
Location:	Cambridge
Founded in:	2004
Sector:	Preventive medicine

e-Therapeutics plc is a drug discovery and development company. It has developed proprietary computational systems to swiftly and accurately analyse and predict how medicines interact with cells in the body in hopes of optimizing the probability of identifying drug candidates with desirable efficacy and minimal side effects.

Website:	http://www.etherapeutics.co.uk
Number of Employees:	11-50
Location:	Hanborough
Founded in:	2003
Sector:	Preventive medicine
Total Funding Amount:	\$66.8M

Evox Therapeutics



Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.

Website:	www.evoxtherapeutics.com
Number of Employees:	11-50
Location:	Oxford
Founded in:	2016
Sector:	AgeTech
Total Funding Amount:	£10M

Freeline Therapeutics



Freeline Therapeutics is a biopharmaceutical company that develops liver directed gene therapies for bleeding disorders and other diseases. Its therapies are based on next-generation proprietary AAV vector platform, with its lead program being a gene therapy to treat haemophilia B.

Freeline Therapeutics was founded in 2015 and is headquartered in London, England.

Website:	http://www.freelinetx.com/
Number of Employees:	11-50
Location:	London
Founded in:	2015
Sector:	Personalized medicine
Total Funding Amount:	\$155.9M

Genedrive Plc



Genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade' business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

Website:	http://www.genedriveplc.com/index.php
Number of Employees:	N/A
Location:	Manchester
Founded in:	2000
Sector:	Personalized medicine
Total Funding Amount:	\$8M

Give & Take Care



Give&TakeCare (G&TC) is a Community Interest Company, based at Brunel University London. The G&TC project is funded by Innovate UK, the government's Innovation Agency for our initial term.

Our aims are:

- To promote person-centred care for older adults (60+) in local communities
- Alleviate issues of loneliness and isolation
- Improve the prospects of care for future generations
- Reduce the ongoing care crisis by expanding the project across the UK

Website:	https://www.giveandtakecare.co.uk/
Number of Employees:	N/A
Location:	UK
Founded in:	2015
Sector:	AgeTech

Graphnet Health



Graphnet Health was formed over 20 years ago and is today the UK's no.1 leading supplier of integrated care record software to the NHS and care services. We are part of the System C and Graphnet Care Alliance.

Website:	https://www.graphnethealth.com/
Number of Employees:	N/A
Location:	UK
Founded in:	N/A
Sector:	AgeTech

GW Pharmaceuticals



GW Pharmaceuticals was founded in 1998 and is listed on both the NASDAQ Global Market (GWPH) and AIM, a market of the London Stock Exchange,. GW is licensed by the UK Home Office to work with a range of controlled drugs for medical research purposes. The Group's lead programme is the development of a product portfolio of cannabinoid prescription medicines to meet patient needs in a wide range of therapeutic indications, including Sativex® Oromucosal Spray and Epidiolex® for childhood epilepsy.

Website:	http://gwpharm.com
Number of Employees:	251-500
Location:	Wiltshire
Founded in:	1998
Sector:	Regenerative medicine
Total Funding Amount:	\$268.1M

Healx is a biotechnology company that develops and offers new therapeutic solutions for patients with rare diseases. The company offers Rareomics, a tool that helps researchers, charities, and individuals keep up with the latest scientific literature on many rare diseases. It also offers Rarepurposing that helps identify existing drug candidates which can help improve the quality of life of patients with rare diseases. Healx was founded in 2014 and is based in Cambridge, United Kingdom.

Website:	http://healx.io/
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2014
Sector:	Personalized medicine
Total Funding Amount:	£1.5M

Too much emphasis is placed on 'doing health' to older people and not enough on creating joy and purpose first, which in turn creates the motivation for self-care and improving personal health and wellbeing'. Our value proposition centres around a physical device that internet enables any TV to allow older people to connect with family and friends in an easy and fear-free manner and in doing so reduces the widening gap of social and digital exclusion. This improved connectivity is the catapult to empowering them to use our platform for self-care especially around falls prevention and other pressing health issues.

Website:	http://www.hellodaisy.org
Number of Employees:	1-10
Location:	London
Founded in:	2017
Sector:	AgeTech

Heptares Therapeutics



Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.

The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, Stabilised Receptors), overcoming a major limiting factor to the development of new drugs targeting this group.

Website:	http://www.heptares.com
Number of Employees:	11-50
Location:	Welwyn Garden City
Founded in:	2007
Sector:	Personalized medicine

Heterogeneous



Heterogeneous is a user-centric genetic data marketplace that connects individuals directly to the research world. It acts as ethical brokers to facilitate a direct connection between you and research institutions.

The company was founded in 2016 and is headquartered in Cambridge.

Website:	http://heterogeneous.co.uk/
Number of Employees:	N/A
Location:	Cambridge
Founded in:	2017
Sector:	Personalized medicine
Total Funding Amount:	£5M

Horizon Discovery



Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company's gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated a catalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12,000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company's own research R&D pipeline.

Website:	http://www.horizondiscovery.com
Number of Employees:	251-500
Location:	Cambridge
Founded in:	2007
Sector:	AgeTech

Howz analyses electricity usage to understand an elderly person's use of everyday objects, learning what is normal activity and alerting the family when things look out of the ordinary.

Website:	http://www.howz.com
Number of Employees:	N/A
Location:	Manchester
Founded in:	N/A
Sector:	AgeTech

hVIVO, a specialty biopharma company with clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.

hVIVO changed its name from Retroscreen Virology in April 2015. The business is a plc quoted on the AIM London Stock Exchange (ticker 'HVO').

Website:	http://hvivo.com
Number of Employees:	501-1000
Location:	London
Founded in:	1988
Sector:	Personalized medicine



iamYiam is a preventive health hub that leverages science, genetics, and lifestyle data to create personalized activities and nutrition plans.

iamYiam delivers personal health plans through science-proved preventive actions. The company's mission is to help their clients select and book the best preventive experiences tailored precisely to who they are (all the way down to their genetic makeup) and the goals they want to achieve - powered by Ycloud, their world class technology platform.

The company's proprietary algorithm provides provides personalised health recommendations supported by scientific research and genetic profiling, to help clients select exactly what is best for their health and well-being from a global network of highly recommended practitioners.

Website:	http://www.iamYiam.com/
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	AgeTech



Around the world, patients with unmet medical needs are frequently driven to seek access to medicines outside the clinical trial and commercial setting. Idis is the leading expert in developing, implementing and managing global Managed Access Programs by which pharmaceutical and biotechnology companies and healthcare providers can respond to the needs of these patients.

Idis has over 27 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from virtually every therapeutic category, impacting the lives of hundreds of thousands of patients. Around the world, a variety of terms are used to describe these programs including “expanded access”, “named patient”, “ATU”, “compassionate use”, and “early access”.

Website:	http://idispharma.com
Number of Employees:	101-250
Location:	Weybridge
Founded in:	1987
Sector:	Personalized medicine



ImmuPharma focuses in developing pioneering and novel drugs in specialist therapeutic areas where there is a distinct lack of existing treatments, avoiding primary care (diseases treated by GPs) where many treatments exist. This is consistent with the trends in the pharmaceutical industry.

Since our foundation, our research strategy has been to work closely with the largest fundamental research organisation in Europe, the Centre National de la Recherche Scientifique, (CNRS) in France. This collaboration enables us to access innovative research with substantial embedded value at a relatively low cost, and to work with many leading scientists and doctors. ImmuPharma has exclusive rights to all its intellectual property assets.

Website:	http://www.immupharma.org
Number of Employees:	1-10
Location:	Westminster
Founded in:	1999
Sector:	Personalized medicine
Total Funding Amount:	\$12.6M

IntelliHep



IntelliHep is a spin-out company developing novel drugs for Alzheimers disease and cancer.

The company is untapping the potential of heparin-based therapeutics in biomedical applications including neurodegeneration and cancer. IntelliHep's compounds have further potential applications in inflammation, angiogenesis, wound healing, regenerative medicine and infectious diseases. IntelliHep is exploiting novel technologies and intellectual property to deliver new heparin-based glycans as novel drug leads for specific diseases including Alzheimer's disease and cancer. This is being achieved through in-house R&D and the development of strategic collaborative alliances with external partners.

IntelliHep has developed from work initiated by the Founders at the Universities of Birmingham and Liverpool, and is currently based in the MerseyBio incubator at Liverpool University.

Website:	http://www.intellihep.com/
Number of Employees:	N/A
Location:	Liverpool
Founded in:	N/A
Sector:	Regenerative medicine



Invizius is developing treatments to help hemodialysis patients live longer, feel better, and suffer fewer cardiovascular complications.

“Despite significant improvements in the quality and efficacy of hemodialysis therapy in recent years, cardiovascular disease (CVD) remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal. With its proprietary H-Guard™ technology, Invizius is addressing the side effects of hemodialysis to help patients feel better, and suffer fewer cardiovascular complications.”

Website:	https://www.invizius.com/
Number of Employees:	N/A
Location:	Edinburgh
Founded in:	2017
Sector:	Preventive medicine
Total Funding Amount:	£1.1M

Jellagen Pty Ltd is a Med-Tech company offering high grade native collagen sourced from jellyfish. Our jellyfish collagen is applicable for tissue engineering, regenerative medicine, stem cell research and a wide variety of cell culture application. We currently supply native collagen for cell culture research supplied in solution or powder.

Website:	http://www.jellagen.co.uk/
Number of Employees:	1-10
Location:	Pembroke Dock
Founded in:	2013
Sector:	Regenerative medicine
Total Funding Amount:	£5.7M

Kalgera is an award winning concept for a digital personal finance manager tailored to the needs of older people.

Every year 5 million older people in the UK fall victim to scams and this forms a large portion of the £38 billion lost each year in the UK to fraud. Kalgera means "good old-age" in Ancient Greek and we want to change this situation and are on a mission to safeguard older people and help them limit financial losses. Kalgera will use Open Banking regulation (also known as Open APIs) and cognitive neurology research to analyse past and present financial behaviour across all financial institutions. Kalgera then uses that data to detect and alert older people and their loved ones to unusual activity so action can be taken to prevent recurrent scams.

Website:	http://www.kalgera.com
Number of Employees:	1-10
Location:	N/A
Founded in:	2016
Sector:	AgeTech



Kareinn is a care planning and daily record system and so much more.

Kareinn helps you utilise technology to ease the burden of evidencing best practice care to the regulators, retain high quality staff and shift the focus from staying up to date to staying ahead of the curve. We have designed our system to capitalize on the data you already gather to support you and your residents with timely insights.

Website:	www.kareinn.com
Number of Employees:	N/A
Location:	N/A
Founded in:	2015
Sector:	AgeTech



Kemuri K-Sockets are designed for the kitchens of people who reject wearables, don't accept changes to their established routines and are beginning to decline in their activities of daily living. Machine learning automatically recognises patterns of movement, eating and drinking before checking every hour for significant changes. After detecting many changes, Kemuri sends alerts to 24/7 alarm response centres, family members or carers. They then take action, depending on the underlying reason for the alert.

Website:	http://www.kemurisense.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	AgeTech

Kraydel is a small, plug and play device enabling the elderly to age safely at home. Packed with sensors, it utilises machine learning to provide 24 hour cover and alerts.

Website:	http://www.kraydel.com
Number of Employees:	N/A
Location:	Belfast
Founded in:	N/A
Sector:	AgeTech
Total Funding Amount:	£1.2M



Lab21 is a rapidly growing healthcare diagnostics business. The company's vision is of providing personalised diagnostic testing for disease identification, disease predisposition and personalised medicine to protect people from the health problems of tomorrow. We believe that 'prevention is better than cure' and aim to provide information that helps to protect people from their health problems of tomorrow. Lab 21 Clinical Laboratory supports healthcare providers and the pharmaceutical and biotechnology industries with technically advanced testing services from its accredited facilities in Cambridge, UK.

The Lab 21 team's experience and know-how is coupled with a rapidly growing portfolio of molecular and viral diagnostics, plus next generation sequencing, pharmacogenetic and patient profiling tests, which all use cutting-edge technology. This unique combination adds value to pharmaceutical, diagnostic and biotech partners – and directly to clinicians or healthcare providers as they treat and monitor their patients. As we move towards truly personalised healthcare, the Lab 21 team contributes today – delivering high-quality information on drugs and patients that provides real clinical insight.

Website:	http://lab21.com
Number of Employees:	51-100
Location:	Cambridge
Founded in:	2005
Sector:	Personalized medicine

With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.

Levicept Ltd is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.

Website:	http://www.leviccept.com/
Number of Employees:	1-10
Location:	Sandwich
Founded in:	2012
Sector:	Personalized medicine
Total Funding Amount:	£12.4M

Lifeline 24



Lifeline24 provide personal alarms for the elderly, disabled and frail within the UK. Our Lifeline Alarms are monitored 24/7 and can provide peace of mind for the whole family. Order online or over the phone today.

Website:	https://www.lifeline24.co.uk
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	AgeTech

LIFNano Therapeutics



LIFNano Therapeutics was founded in 2013 as a spin-out from the University of Cambridge, progressing to a clinical stage Nano-Bio-Med company specifically focused on targeted delivery of the biologic, Leukaemia Inhibitory Factor (LIF)..

Website:	http://www.lifnano.com/
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2015
Sector:	Preventive medicine
Total Funding Amount:	£1M

LIFT BioSciences



LIFT BioSciences is a socially-minded Biotech start-up developing a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumours using its innate immunity platform, known as Leukocyte Infusion Therapy (LIFT). LIFT BioSciences Ltd was set-up with Prof Zhen Cui of Wake Forest University, a leading pioneer in LIFT, following his discovery of a cancer resistant (SR/CR) mouse that proved to have transferable innate immunity. The goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy (LIFT).

Website:	http://www.liftbiosciences.com/
Number of Employees:	N/A
Location:	London
Founded in:	2016
Sector:	Personalized medicine
Total Funding Amount:	£306K

Memrica



Memrica Prompt is a digital back up memory, which helps people live well with conditions such as early dementia, mild cognitive impairment, strokes or brain injuries.

Website:	www.memricaprompt.com
Number of Employees:	1-10
Location:	Birmingham
Founded in:	2013
Sector:	AgeTech

Methuselah Health



Methuselah Health is a drug discovery company founded in 2015 by Index Ventures to study the role of proteome instability in a number of human diseases linked to ageing.

Website:	www.methuselah-health.com
Number of Employees:	N/A
Location:	Cambridge
Founded in:	2015
Sector:	AgeTech

Michelson Diagnostics



Michelson Diagnostics is the developer and manufacturer of products based on Multi-Beam Optical Coherence Tomography (OCT), the uniquely powerful, innovative optical imaging technology that is capable of imaging living tissue microstructure at $< 10 \text{ \AA}\mu\text{m}$ resolution, in real time, to depths of 1 mm or more.

Website:	http://www.md-ltd.co.uk
Number of Employees:	11-50
Location:	Orpington
Founded in:	2006
Sector:	Preventive medicine
Total Funding Amount:	\$10.8M

Micrima



Micrima Ltd. spun out from research at the University of Bristol. The Micrima team is developing radio-wave technology for detecting breast cancer. The technology is non-invasive, non-ionising and inexpensive.

The imaging technology has received extensive validation in the laboratory and is now undergoing first human use trials.

Website:	http://www.micrima.com
Number of Employees:	1-10
Location:	Bristol
Founded in:	2005
Sector:	Preventive medicine
Total Funding Amount:	\$18.8M

MiiCARE



Micrima develops a non-invasive and a non-ionizing radio wave technology for detecting breast cancer.

Website:	http://miicare.co.uk/
Number of Employees:	N/A
Location:	London
Founded in:	N/A
Sector:	AgeTech

Minatx



Harnessing the innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients' cells. We are applying our technology and clinical know-how to transform the therapy landscape of severe liver diseases. Our initial product candidate will achieve clinical proof of concept in 2017.

Website:	http://www.minatx.com
Number of Employees:	1-10
Location:	London
Founded in:	2008
Sector:	Personalized medicine

Molecular Vision



Molecular Vision is an optical detection company that offers a platform technology solution for versatile optical detection in a portable format. It carries an integration of low-cost organic light emitting diodes and organic photodetectors with analytical devices. This enables the realization of hand-held disposable medical diagnostics devices for point-of-care testing. Additional applications for the portable quantitative analytical devices include in-the-field veterinary testing, food and plant testing, environmental monitoring, and homeland security. Molecular Vision was founded in 2001 and is based in London, United Kingdom.

Website:	http://www.molecularvision.co.uk/
Number of Employees:	11-50
Location:	London
Founded in:	2001
Sector:	Personalized medicine
Total Funding Amount:	\$500K

Mologic



Two quirky scientists vowed to make the world a better place. After learning their trades in some of the world's biggest scientific organisations, Paul and Mark Davis (father and son team with a striking resemblance to Pinky and the Brain established Mologic to do as much good as possible in healthcare and education. They want to improve patient care and quality of life, and break new ground in exciting fields of research (unlike Pinky and the Brain who wanted to take over the world).

Website:	http://mologic.co.uk/
Number of Employees:	11-50
Location:	Thurleigh
Founded in:	2003
Sector:	Personalized medicine
Total Funding Amount:	\$9.4M

Monica Healthcare



Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.

Website:	http://www.monicahealthcare.com
Number of Employees:	11-50
Location:	Nottingham
Founded in:	2005
Sector:	Preventive medicine
Total Funding Amount:	\$5.9M



Based in Cambridge (UK), Mursla is a startup developing a diagnostic device that leverages proprietary nanostructures to significantly improve cancer detection. Our technology has the potential to simplify the whole cycle of cancer management through utilizing a novel, non-invasive procedure called liquid biopsy.

We provide a competitive and differentiated proposal with superior predictive power potential by identifying panels of circulating wild-type and mutant proteins in blood at the point-of-care. Proteins are the key mediators of regulated or unregulated cellular activities in contrast to circulating nucleic acids assessed by Next-Gen Sequencing Technologies.

Website:	http://mursla.com
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2017
Sector:	Preventive medicine
Total Funding Amount:	\$900K

Nanokick Technologies



Nanokick Technologies develops a spin-out, focussing on nanovibrational bioreactor technology for bone regeneration from stem cells.

Nanokick Technologies is an emerging spinout from the Universities of Glasgow and West of Scotland. The company's novel process technology utilizes nanoscale vibration as a means of converting adult stem cells into bone building cells (osteoblasts). This presents potential products for academia, drug discovery and even clinical use.

Website:	http://www.nanokick.com/
Number of Employees:	N/A
Location:	Glasgow
Founded in:	N/A
Sector:	Regenerative Medicine

nanoTherics gene transfection studies have shown a significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst, importantly, maintaining the viability of the transfected cells. These two key attributes afford a significant competitive advantage over currently available systems.

nanoTherics's mission is to position its novel gene transfection technology as the new "gold standard" for transfection, underpinning the research and development of current and future gene therapy programmes.

Website:	http://www.nanotherics.com
Number of Employees:	11-50
Location:	Stoke-on-trent
Founded in:	2007
Sector:	Personalized medicine
Total Funding Amount:	£1.1M

Nemaura Pharma



A private specialist biotech company, Nemaura Pharma is strategically positioned to work with global pharmaceutical companies, as well as new biotechnology companies, to successfully bring both new and old drugs to patients in superior delivery formulations and systems. Ultimately, we aim to improve patient lifestyle and quality of life. Our advanced drug delivery systems are designed to increase the effectiveness and safety of therapeutic drugs, while also reducing complications due to patient non-compliance, and mitigating the side effects of less efficient delivery systems.

Website:	http://www.nemaura.co.uk/
Number of Employees:	11-50
Location:	Loughborough
Founded in:	N/A
Sector:	Personalized medicine
Total Funding Amount:	\$5M

NeoPhore



NeoPhore, based in Cambridge, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Cancer neoantigens are known to stimulate the immune system and potentially be a weak spot in a tumour cell's defence mechanisms. The Company's approach targets genetic mechanisms that both clinical and lab studies suggest will promote neoantigen creation and diversity across numerous cancers. Using these insights, the Company aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Website:	http://www.neophore.com/
Number of Employees:	N/A
Location:	Cambridge
Founded in:	N/A
Sector:	Preventive medicine
Total Funding Amount:	£3M

NeRRe Therapeutics



NeRRe Therapeutics Ltd. operates as a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists. The company was founded in 2012 and is based in Stevenage, United Kingdom.

Website:	http://nerretherapeutics.com/
Number of Employees:	11-50
Location:	Herefordshire
Founded in:	2012
Sector:	Personalized medicine
Total Funding Amount:	\$47M


Nightstar Therapeutics



NightstarRx Ltd. is a U.K. startup company. Gene therapy is the use of a gene to treat disease. The approach could enable treatments for a several rare conditions caused by mutations in a single gene.

Website:	https://www.nightstartx.com/
Number of Employees:	11-50
Location:	London
Founded in:	2013
Sector:	Regenerative medicine
Total Funding Amount:	\$174.6M

Nuclera Nucleics



Nuclera is a next-generation DNA synthesis company creating tailored solutions for the synthetic biology, industrial enzyme engineering, and pharmaceutical industries. Our proprietary enzyme-mediated DNA synthesis platform will enable the rapid and cost-effective production of highly accurate, ultra-long DNA strands. We aim to be the key provider of long-length variant DNA and genome libraries for protein, biological pathway, and ultimately genome-scale engineering.

Website:	http://www.nuclera.com/
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2013
Sector:	Personalized medicine
Total Funding Amount:	£828K

Open Bionics



They use 3D printing to make their devices customized for each customer and accessible by anyone!
They're developing the perfect medical grade materials to give their hands the right strength and grip and to make them last.

Website:	http://openbionics.com
Number of Employees:	11-50
Location:	Bristol
Founded in:	2014
Sector:	Personalized medicine
Total Funding Amount:	\$2.9M

Open Inclusion

open.

Open Inclusion helps businesses understand the needs of their broader customer segments as well as their workforce. They do this primarily through asking people with lived experience of access needs. Our UK wide panel of over 350 people, with a range of impairments or just getting older, engage with us through a broad variety of methodologies. These cover quantitative, qualitative, behavioural and attitudinal research. We also conduct market research and value analysis drawing on our extensive database of nationally representative statistics covering all major age, disability and impairment categories.

Website:	https://openinclusion.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	AgeTech

Optibiotix Health



OptiBiotix develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

Website:	http://www.optibiotix.com/
Number of Employees:	N/A
Location:	Heslington
Founded in:	2012
Sector:	Personalized medicine
Total Funding Amount:	£1.5M

Orca Pharmaceuticals



Orca Pharmaceuticals, a new biotechnology start-up focused on treating autoimmune diseases. Funding is from BioMotiv, a Cleveland, Ohio based therapeutics accelerator affiliated with The Harrington Project, and the New York University Innovation Venture Fund. The company, located in Oxford UK, is based on technology developed by inventors from New York University (NYU) in collaboration with the founders in the United Kingdom.

Website:	http://orcapharmaceuticals.com
Number of Employees:	N/A
Location:	Abingdon
Founded in:	2012
Sector:	Personalized medicine
Total Funding Amount:	\$2.5M

Orchard Therapeutics



Orchard Therapeutics is a biotechnology company incorporated in September 2015 and dedicated to bringing transformative gene therapies to patients with serious and life-threatening orphan diseases. Our programmes will use the potential of ex-vivo autologous haematopoietic stem cell gene therapy to restore normal gene function in severe and life-threatening inherited disorders.

We work in partnership with the world's leading research centres to harness the life-giving potential of gene therapy. Our mission is to translate results from pre-clinical and early clinical research into commercially approved gene therapies for patients around the world.

Website:	http://www.orchard-tx.com/
Number of Employees:	1-10
Location:	London
Founded in:	2015
Sector:	Regenerative medicine
Total Funding Amount:	\$160.5M

Orthogem Limited is a UK based biomaterials company, with an intense focus on the discovery and development of advanced Synthetic Bone Graft (SBG) material.

Website:	http://www.orthogem.com
Number of Employees:	1-10
Location:	Nottingham
Founded in:	2000
Sector:	Regenerative medicine

Oxford Biodynamics



Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therap.

Website:	https://www.oxfordbiodynamics.com/
Number of Employees:	N/A
Location:	Oxford
Founded in:	2007
Sector:	Personalized medicine

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture.

Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient's cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body.

Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes.

Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.

Website:	http://www.oxfordbiomedica.co.uk/
Number of Employees:	51-100
Location:	Oxford
Founded in:	1995
Sector:	Regenerative medicine

Oxford Gene Technology



Oxford Gene Technology provides world-class genetics research solutions to leading clinical and academic research institutions.

Website:	https://www.ogt.com/
Number of Employees:	101-250
Location:	Oxfordshire
Founded in:	1995
Sector:	Personalized medicine

Oxford Genetics



Oxford Genetics Ltd is a UK based biotechnology company specialising in the production of versatile cloning plasmids for research in academic and biotechnology institutions. they also provide custom cloning and DNA synthesis. All of their products are free of intellectual property restrictions.

Website:	http://oxfordgenetics.com
Number of Employees:	1-10
Location:	Upper Heyford
Founded in:	2011
Sector:	Personalized medicine
Total Funding Amount:	£10.3M



OxStem plans to develop small molecule drugs that can activate repair mechanisms that already exist within the body. Building on decades of experience in medicinal chemistry, OxStem will design drugs that can programme resident stem and stem-like cells in situ to treat currently untreatable age-related conditions.

Website:	www.oxstem.co.uk
Number of Employees:	1-10
Location:	Oxford
Founded in:	2013
Sector:	Regenerative medicine
Total Funding Amount:	£16.9M

Patients Know Best



Patients Know Best is the world's first patient-controlled medical records system. It is a fully secure online tool which enables patients to better organise, manage and control their own health care provision – it also saves the time of physicians through allowing secure, online consultations.

Founded by Dr. Mohammad Al-Ubaydli, a physician, programmer and expert in IT in healthcare, Patients Know Best has won social enterprise awards for its focus on patient care. Patients Know Best's first customers include Great Ormond Street Hospital, St Mark's Hospital, Novartis and NHS South Devon. Patients Know Best integrates fully into the NHS secure network and is available for use by any patient with any clinician anywhere in the world. Patients Know Best complies fully with UK NHS and data protection requirements as well as the EU data protection act and US HIPAA legislation for dealing with medical data.

Website:	https://www.patientsknowbest.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2008
Sector:	Personalized medicine
Total Funding Amount:	\$7.9M

Perfectus Biomed



They are a microbiological services provider that provide our clients with a research based approach to microbiological testing, whilst recognising the client's need for a rapid turnaround and a personalised service. We specialise in bespoke assays with a primary focus on biofilm testing.

They appreciate that not all products are appropriate for standard testing assays and therefore we work closely with our clients to develop methods that are suitable for the testing of novel products.

They offer an extremely customer focused service that includes regular feedback, consultancy, method development and report writing. In addition we produce conference abstracts and posters based on the data we produce.

Website:	http://perfectusbiomed.com
Number of Employees:	1-10
Location:	Cheshire
Founded in:	2012
Sector:	Preventive medicine
Total Funding Amount:	£300K

Phico Therapeutics



Phico Therapeutics is developing a unique antibiotic technology to address one of the most urgent challenges facing medicine today: how to destroy multi-drug resistant bacteria, the so-called "superbugs".

Phico's™ patented platform utilizes an antibacterial protein, SASP, to inactivate bacterial DNA and cause rapid destruction of target bacteria. SASPject™ is a new class of antibiotic which could provide many advantages over conventional antibiotic classes.

Website:	http://www.phicotherapeutics.co.uk
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2000
Sector:	Personalized medicine
Total Funding Amount:	£9.6M

Phoqus Pharmaceuticals



Phoqus group is a specialty pharmaceutical company, engages in the development and commercialization of drugs that meet unmet medical needs using the electrostatic deposition technology. Its primary product Chronocort is a Phase II clinical trial product used for the treatment of congenital adrenal hyperplasia and Addison's disease. The company's drug delivery platform, Qtrol, which is derived from electrostatic deposition, enables solid oral dosage forms, such as tablets to be coated in a controlled and precise manner that could then be used to modify the way that a drug is released into the body.

Website:	http://www.phoqus.eu
Number of Employees:	N/A
Location:	West Malling
Founded in:	1998
Sector:	Personalized medicine

PhoreMost



PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new 'druggable' target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel 'targeted' therapies more efficiently to market and pass these cost savings onto patients.

Website:	http://www.phoremmost.com
Number of Employees:	1-10
Location:	Cambridge
Founded in:	2014
Sector:	Personalized medicine
Total Funding Amount:	\$18.8M

Physiomics



Physiomics plc combines systems biology with cutting edge mathematics to develop models that streamline the drug discovery and development process. Virtual Tumour, the company's lead service, is used to optimise the dosing and scheduling of oncology drugs in pre-clinical and clinical trials. This optimisation improves the efficacy of combinations and streamlines the drug development process.

Website:	http://www.physiomics-plc.com/
Number of Employees:	N/A
Location:	Oxford
Founded in:	2002
Sector:	Personalized medicine

Plasticell



Plasticell is a privately held biotechnology company using novel cell culture and drug discovery platforms to produce regenerative small molecule drugs.

Plasticell aims to develop drugs by elucidating the biochemical mechanisms that control the proliferation and differentiation of stem cells, the master cells responsible for tissue development and repair.

Website:	http://www.plasticell.co.uk
Number of Employees:	11-50
Location:	London
Founded in:	2002
Sector:	Regenerative medicine
Total Funding Amount:	£4.2M



PneumaCare is focused on development of products for diagnosis and monitoring of respiratory disease using novel 3D imaging technology, developed by the University of Cambridge. The Company's first product is a non-contact respiratory monitoring system for physician assessment, called PneumaScan, which has clinical applications in a number of medical environments. Using PneumaScan, patients can be assessed while breathing naturally or performing spirometric manoeuvres without the need to breathe into, interact with or contact the measuring device. PneumaCare's products, the PneumaScan family, enables clinicians to access many different patient-types, many of which are not within the capabilities of current clinical devices. The system is being constantly evaluated in clinical practice, currently at Addenbrooke's Hospital in Cambridge, Great Ormond Street Children's Hospital in London and in development laboratories at its design and manufacturing partner, Plextek. PneumaScan produces standard medical outputs for a broader portion of the population because it observes patients from a distance and does not impede the respiratory system as with current spirometer technology. Measuring from a distance means lower infection risk, less harm, reduced patient discomfort and minimal instrument running costs from having to replace or sterilise parts which have contacted the patient.

Website:	http://www.pneumacare.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2008
Sector:	Preventive medicine
Total Funding Amount:	£3.4M

Precision Medicines



Precision Medicines is dedicated to improving the lives of cancer patients through developing novel targeted medicines.

Precision Medicines is a clinical stage biotechnology company focussed on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use.

The development programs are focused on cancer sub types using a precision or personalized medicine approach, whereby therapies are co-developed with companion biomarkers to target the specific drivers of cancers.

Website:	http://www.precimed.com/
Number of Employees:	N/A
Location:	Alderley Edge
Founded in:	N/A
Sector:	Personalized medicine

Premaitha Health



Premaitha Health is a molecular diagnostics company employing next generation DNA analysis technology to develop

Website:	http://premaitha.com
Number of Employees:	11-50
Location:	Manchester
Founded in:	2013
Sector:	Personalized medicine

Proteome Sciences



Proteome Sciences is a London (UK) and Frankfurt (Germany) based SME with expertise in proteomics and biomarker research. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies.

Website:	http://www.proteomics.com/
Number of Employees:	N/A
Location:	London
Founded in:	1993
Sector:	Personalized medicine

Proximagen



Proximagen is a publicly traded neuroscience research company focused on drug development for neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease.

Website:	http://www.proximagen.com
Number of Employees:	11-50
Location:	London
Founded in:	2003
Sector:	Personalized medicine
Total Funding Amount:	\$96.5M

Psioxus Therapeutics



PsiOxus Therapeutics Ltd develops novel therapeutics for serious diseases with a particular focus upon cancer. They are an Oxford based development stage biotechnology company with world leading scientists and a highly experienced management team.

Their approach is to combine macromolecular elements including viruses, polymers and other macro-molecules to produce novel patent protected therapeutics.

Website:	http://www.psioxus.com/
Number of Employees:	11-50
Location:	Oxfordshire
Founded in:	2006
Sector:	Regenerative medicine
Total Funding Amount:	£52.6M

Q Chip (Acquired by Midatech Pharma)



Q Chip is a biopharmaceutical drug delivery company developing a range of sustained-release biogeneric and biotherapies products (Q-Sphera).

Website:	http://www.q-chip.com
Number of Employees:	11-50
Location:	Cardiff
Founded in:	2003
Sector:	Personalized medicine
Total Funding Amount:	\$10.3M

QuantuMDx Group



QuantuMDx Group is a young and vibrant medical devices company developing hand-held and portable low cost diagnostic & genomic sequencing platforms capable of supporting the delivery of personalised medicine across both developed and developing nations.

Website:	http://quantumdx.com
Number of Employees:	11-50
Location:	Newcastle Upon Tyne
Founded in:	2008
Sector:	Regenerative medicine
Total Funding Amount:	\$26.3M

Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases. Our initial focus is on developing therapies to reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve. Quethera is working alongside world leaders in the glaucoma field to design clinical trials capable of examining the efficacy and safety of novel therapies in patients who lose parts of their visual field at an accelerated rate (fast-progressors). The company has expertise in gene therapeutic design and development sufficient to progress its pipeline through preclinical testing and into clinical development.

Website:	http://www.quethera.co.uk/
Number of Employees:	N/A
Location:	Babraham
Founded in:	2013
Sector:	Personalized medicine



The Care Act encourages establishing the Life Story of a person, with the aim of facilitating person centred care and enabling providers to build activity and care around the particular wishes, interests and needs of each person. This usually involves pen and paper. ReMe has digitised the process, enabling family to participate and match their profile with automatically generated internet content. The result is a life vibrantly illustrated with bespoke content that grows day by day.

Website:	https://www.remindmecare.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	AgeTech

ReNeuron Group



ReNeuron Group Plc engages in the research, development, and commercial exploitation of stem cell technologies for therapeutic and non-therapeutic applications.

It develops stem cell therapies for a range of neurodegenerative diseases and other conditions, including Parkinson's disease, Type 1 diabetes, and diseases of the retina. The company's therapeutic product pipeline includes ReN001, a pre-clinical development stage therapy for disabled stroke patients. Its other therapeutic and non-therapeutic programs in pre-clinical trials comprise ReN002 for diabetes, ReN003 for retinal diseases, ReN004 for Parkinson's disease, and ReN005 for Huntington's disease. ReNeuron Group also develops and markets neural stem cell lines that include ReNcell VM and ReNcell CX. The company was founded in 1997 and is headquartered in Guildford, the United Kingdom.

Website:	http://www.reneuron.com
Number of Employees:	11-50
Location:	Guildford
Founded in:	1997
Sector:	Regenerative medicine
Total Funding Amount:	\$164.3M

Rexgenero



Rexgenero is a leading regenerative medicine company and developer of advanced cell-based therapeutics for the treatment of serious diseases that are poorly treated with existing therapies. They are conducting clinical trials with their cellular therapies with the intention of obtaining marketing authorization in Europe, the United States and other markets. Their treatments draw on an exceptional understanding of the fundamental science of cell therapies. Their current cell therapies have been developed by the Andalusian Health Authority (Servicio Andaluz de Salud) and Andalusian Initiative of Advanced Therapies and they aim to work with them to develop further cell therapies to treat other indications with high unmet medical needs.

Website:	http://www.rexgenero.com/
Number of Employees:	N/A
Location:	London
Founded in:	N/A
Sector:	Regenerative medicine
Total Funding Amount:	£1.4M

Rightangled



At Rightangled Diagnostics, they believe that revealing specific information encoded within the DNA helps to close the genetic information gap between practitioners and patients, bringing them together one step closer to a satisfying, safer and more successful treatment regimen.

Through their platform, they want to move away from the traditional "one-size-fits-all" era into the personalised treatment era. They believe that targeted genetic information can help your medical practitioners find interventions and therapies tailored around your unique genes, so that they precisely match up with what your body needs. They want to remove the constraints around accessing qualified specialists - that is why they link patients to practitioners online, to provide you with access to quality healthcare from the comfort of your home.

Website:	https://www.rightangled.com
Number of Employees:	N/A
Location:	London
Founded in:	N/A
Sector:	Personalized medicine
Total Funding Amount:	£866.6K

Rogue Resolutions



Rogue Resolutions, Ltd., a Cardiff, UK-based start up that provides integrated solutions and services allowing non-invasive neurological treatment methods.

Website:	http://www.rogue-resolutions.com
Number of Employees:	1-10
Location:	Cardiff
Founded in:	2010
Sector:	Personalized medicine

Roslin Cells



Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).

Website:	http://roslincells.com/
Number of Employees:	11-50
Location:	Edinburgh
Founded in:	2006
Sector:	Personalized medicine

SAGE Therapeutics



SAGE Therapeutics is dedicated to the health and wellbeing of patients with central nervous system (CNS) disorders. Our mission is to discover, develop and deliver novel medicines for many of today's most debilitating and disabling CNS disorders by leveraging compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers.


Website:	http://www.sagerx.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2011
Sector:	Regenerative medicine
Total Funding Amount:	\$438M



Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. Preliminary evidence from Part 1 of the study showing that SCIB1 produced an immune response which might be associated with clinical benefit in patients with malignant melanoma was released in December 2012.

Website:	http://www.scancell.co.uk
Number of Employees:	11-50
Location:	Nottingham
Founded in:	1996
Sector:	Personalized medicine
Total Funding Amount:	£2.6M

Sensio Air



White Lab is a healthcare analytics company based in London the US and Lebanon. With a focus on respiratory conditions, the company works to develop cutting-edge technology that identifies airborne particles and helps people predict, prevent and manage the unwanted symptoms that come with asthma and allergies.

Co-founded by professor at UCL and industrial designer Cyrille Najjar and PhD in neuroscience Dr. Eve Tamraz; White Lab unveiled Sensio AIR in 2016. A device and mobile application that allows users to monitor their health at the touch of a screen,

Sensio AIR was designed to improve the quality of life for asthma and allergy sufferers everywhere. Using real-time data and locations from across the world, the app uses AI and Machine Learning to define the correlation between user symptoms and environmental factors or allergens in their vicinity.

Website:	http://www.wlab.io
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	Preventive medicine



Sernova Corp., a health sciences company, focuses on the development and commercialization of medical technologies in the United States and Canada. Its proprietary platform technologies include Cell Pouch System, a device providing a natural organ-like environment for therapeutic cells, such as insulin producing islets for diabetics; and Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. The company also focuses to commercialize products for the treatment of Parkinson's, spinal cord injury, and haemophilia diseases. Sernova Corp. is headquartered in London, Canada.

Website:	http://sernova.com
Number of Employees:	1-10
Location:	London
Founded in:	N/A
Sector:	Personalized medicine
Total Funding Amount:	\$4.3M



Sistemic Ltd. provides drug discovery and repositioning services based on its SistemRNA compound-centric drug discovery technology. It offers services to the biotechnology and pharmaceutical sectors relating to the biology of small RNAs, including microRNAs in cancer and other diseases. The company was founded in 2009 and is based in Glasgow, the United Kingdom with an additional office in Boston, Massachusetts.

Website:	http://www.sistemic.co.uk/index.html
Number of Employees:	11-50
Location:	Glasgow
Founded in:	2009
Sector:	Personalized medicine
Total Funding Amount:	\$1M

SkyePharma (Acquired by Vectura)



SkyePharma has been established in 1996 and is a leading speciality drug delivery company with a proven range of oral and inhalation technologies.

SkyePharma strives to deliver a clinical benefit for patients by using its multiple delivery technologies to create enhanced versions of existing pharmaceutical products as well as products incorporating new chemical entities. Combining established pre-clinical, clinical and regulatory expertise with the capability to formulate and manufacture drugs, both for clinical studies and commercial sale, SkyePharma identifies and develops potential new therapeutic products for out-licensing as well as working with partners to develop their concepts through to marketable products.

Website:	http://www.skyepharma.com
Number of Employees:	101-250
Location:	London
Founded in:	1996
Sector:	Personalized medicine

Solentim



Commercial cell line development for biopharmaceutical production is a high value process that is intrinsically expensive and takes a significant amount of time.

Solentim is dedicated to the development of smart tools that shorten the steps in the upstream cell line development workflow and accelerate timelines.

Their products are the Cell Metric™ series for clone screening, growth and stability measurements.

Website:	http://www.solentim.com/
Number of Employees:	11-50
Location:	Wimborne
Founded in:	2010
Sector:	Regenerative medicine

Sphere Fluidics



Sphere Fluidics develops novel single cell analysis systems for scientists searching for rare and valuable biological variants across research, therapeutic, bioproduction and diagnostic applications. Their flexible technology, innovative products and range of services help you to boost throughput and sensitivity, while reducing costs and saving time.

Website:	http://www.spherefluidics.com
Number of Employees:	11-50
Location:	Cambridge
Founded in:	2010
Sector:	Personalized medicine
Total Funding Amount:	\$15M

StoriiCare



StoriiCare is setting the gold standard for person-centred care. Our cloud based software is used by senior living communities, nursing homes and home care agencies, enabling families to connect with their loved ones and care staff to digitally record their care.

Our HQ is in Glasgow, Scotland, with a remote office in San Francisco, California.

To learn more about StoriiCare, visit www.storiicare.com To look at our job listings, visit <https://angel.co/storiicare>

Website:	https://storiicare.com/
Number of Employees:	11-50
Location:	Glasgow City
Founded in:	2014
Sector:	AgeTech
Total Funding Amount:	£580K

Suisse Life Science Group plc



Suisse Life Science is a biological big data analytics company that has developed a knowledge-discovery platform to extract cause-effect relationships directly from genetic interpretation – and at scale – linking them to lifestyle data from consumer devices in real time to provide actionable recommendations.

The goal is to leverage these capabilities to transform health from an expert-driven field – with poor predictive power and large gaps in its fundamental understanding of human biology – and transforming it into a data-driven predictive science that makes it as easy as possible for individuals of all ages to take a more active role in managing their health.

Website:	https://suisselifescience.com
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	Personalized medicine

Swift Molecular Diagnostics



Swift Molecular Diagnostics is a molecular diagnostic company that wants to revolutionise the field of diagnostics and make it accessible to everybody and everywhere. They are developing a novel technology for cost-effective, rapid, easy-to-use and highly specific genetic “yes or no” test that can be performed directly by the side of the patient in under 15 minutes. For the first time in history of molecular diagnostic, anyone will be able to use a DNA test regardless of his location, equipment and training.

Website:	https://www.swiftdx.co.uk/
Number of Employees:	N/A
Location:	Cambridge
Founded in:	N/A
Sector:	Personalized medicine

Synpromics Ltd



Synpromics develops and commercializes synthetic promoters to control gene expressions and regulations. The company was founded in 2010 and is based in Edinburgh, United Kingdom.

Website:	http://www.synpromics.com/
Number of Employees:	1-10
Location:	Edinburgh
Founded in:	2010
Sector:	Personalized medicine
Total Funding Amount:	£9.2M

T7 Technology



At T7 Technology we understand that nothing replaces face to face support, but sometimes all you need is reassurance, without the need for a visit or care in your home. Perhaps its someone on the end of the phone just in case, or to let your your family and friends know everything is okay. There are also those times when you may need something more, and not just in an emergency but ideally before it happens.

We created T7 Tech to offer that reassurance and response. We have developed discreet digital monitoring technologies that not only allow us to understand your emergency needs (in the same way that traditional telecare services do) but also to pre-empt some of your care needs and help you make decisions to keep you safe and well.

Website:	http://www.t7.technology
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	Personalized medicine

TC BioPharm




TC BioPharm's mission is to develop and commercialise innovative cell-based products to treat disease, improving patient health and Quality of Life.

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell®, in renal cell carcinoma, non-small cell lung cancer and melanoma patients.

Website:	http://www.tcbiopharm.com/
Number of Employees:	11-50
Location:	Holytown
Founded in:	2013
Sector:	Personalized medicine
Total Funding Amount:	\$34M

Theolytics



Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies. The company was formed in 2017 to drive the development of a pipeline of novel clinical trial candidates, and is led by a team that combines over 40 years of experience in oncolytic virus development. The company uses an adenovirus platform to develop targeted, self-amplifying therapeutic agents, and aims to deliver innovative cancer care to millions of people in need worldwide.

Website:	https://www.theolytics.com/
Number of Employees:	N/A
Location:	Oxford
Founded in:	N/A
Sector:	Preventive medicine

Tissue Regenix



Tissue Regenix was founded in May 2006, to commercialise innovative technologies in regenerative medicine. The underpinning science was developed over the last decade in the world-leading Institute for Medical and Biological Engineering at the University of Leeds by Professors John Fisher and Eileen Ingham. The research has received in excess of Â£4 million grant funding to date from UK research councils (EPSRC, BBSRC) and the Children's Heart Surgery Fund.

Website:	https://www.tissueregenix.com/
Number of Employees:	51-100
Location:	York
Founded in:	2006
Sector:	Regenerative medicine
Total Funding Amount:	£685K

Touch Bionics



Touch Bionics Inc., is a Livingston, Scotland, UK-based developer of advanced upper-limb prosthetics.

Website:	http://www.touchbionics.com/
Number of Employees:	N/A
Location:	Livingston
Founded in:	2005
Sector:	Personalized medicine
Total Funding Amount:	£5.8M

Tunstall Healthcare Group



Tunstall is a leading provider of telecare/telehealth solutions. Operating in more than 30 countries and employing over 1,200 people, Tunstall supports 2.5 million people around the world. Tunstall's philosophy is simple - to protect, support and care for people - by providing healthcare technology and services that enable anyone requiring support and reassurance, such as older people or those with long term needs, to lead an independent life with dignity and reassurance.

Tunstall provides complete and fully-integrated telecare and telehealth solutions for home, assisted living and specialist care environments, hospital communication systems, associated support services, response centre software systems and monitoring services.

Website:	http://www.tunstall.co.uk
Number of Employees:	1001-5000
Location:	North Yorkshire
Founded in:	1957
Sector:	AgeTech



ukactive exists to improve the health of the nation by getting more people, more active, more often. ukactive provides services and facilitates partnerships for a broad range of organisations, all of which support their vision and have a role to play in achieving that goal.

Thier long-standing and uncompromising vision is to get more people, more active, more often. We are committed to improving the health of the nation through promoting active lifestyles. They achieve this by facilitating big impact partnerships, campaigning and providing world class membership services. We exist to serve any organisation with a role in getting more people, more active, more often. They provide a supportive, professional and innovative platform for our partners to succeed in achieving their goals and create the conditions in which our sector can grow. ukactive – together achieving more

Website:	https://www.ukactive.com/
Number of Employees:	N/A
Location:	N/A
Founded in:	N/A
Sector:	Personalized medicine



Valirx Plc, an investment holding company, engages in the research and development of oncology therapeutics and diagnostics in the United Kingdom. The company principally offers VAL 101 that acts to shut down the Bcl-2 gene, a proto-oncogene. It develops human papilloma virus diagnostic products based on the Nucleosomics, a platform for non-invasive tests for early cancer diagnosis based on epigenetic signal changes associated with malignancy; and HyperGenomics, a platform for differential diagnostic and prognostic tests in cancer, as well as testing for personalized medicine. The company also develops GeneICE compounds, which treat various diseases by acting to shut down harmful genes and prevent their expression. Valirx Plc is based in London, the United Kingdom.

Website:	http://www.valirx.com
Number of Employees:	N/A
Location:	London
Founded in:	2000
Sector:	Personalized medicine
Total Funding Amount:	£800K

Verona Pharma



Verona Pharma is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as asthma, allergic rhinitis (hay fever), chronic obstructive pulmonary disease (COPD) and cough.

Website:	http://www.veronapharma.com
Number of Employees:	N/A
Location:	London
Founded in:	2005
Sector:	Personalized medicine
Total Funding Amount:	\$77.1M

Vertex Pharmaceuticals



Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company's strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex's product pipeline is focused on viral diseases, cystic fibrosis, inflammation, autoimmune diseases, cancer, and pain

Website:	http://www.vrtx.com
Number of Employees:	1001-5000
Location:	Abingdon
Founded in:	1989
Sector:	Regenerative medicine
Total Funding Amount:	\$600.4M



Vida's mission is to empower. With technology we empower the elderly, they empower their families, and they empower their carers. Their platform enables a circle of care connecting healthcare providers to the elderly. Everything we do is centred around the cared for, their family and their carers.

They have a wide network of qualified, experienced and trusted carers. They only accept the top 10% of applicants who must have a minimum of two years' experience. Vida carers must pass our strict in-house recruitment and training processes. Behind them sit a team of leading and award winning care managers and care co-ordinators.

Website:	https://vida.co.uk
Number of Employees:	11-50
Location:	London
Founded in:	2016
Sector:	Personalized medicine
Total Funding Amount:	€1M

Videregen Limited operates as a regenerative medicine company.

Videregen's goal is to offer the world's first commercially available organ replacement products to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient's own stem cells are added, creating a bespoke organ replacement.

Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world's first commercially available organ replacements for these conditions, reducing healthcare costs and improving the quality of life for patients.

Website:	http://www.videregen.com/
Number of Employees:	11-50
Location:	Liverpool
Founded in:	2011
Sector:	Regenerative medicine
Total Funding Amount:	£3.1M

VirionHealth



VirionHealth is a biotechnology company developing ground-breaking therapies for respiratory viral infections. Its pioneering DI platform technology aims provide a new class of biological antiviral active across a range of infectious diseases.

Website:	http://www.virionhealth.com
Number of Employees:	N/A
Location:	Coventry
Founded in:	2017
Sector:	Personalized medicine
Total Funding Amount:	£13M

Virttu Biologics



Virttu is a privately held biotechnology company, which has pioneered the development of oncolytic viruses for treating cancer. Virttu Biologics Limited is a wholly-owned subsidiary of TNK Therapeutics, Inc. and part of the group of companies owned by Sorrento Therapeutics, Inc. Virttu has pioneered the development of oncolytic viruses for treating cancer. Although viruses naturally kill the cells they infect, weakened viruses have been used in medicine for centuries as vaccinations against the infectious diseases they cause. Scientists at Virttu have reprogrammed this ability in a common human virus so that it targets and kills only cancer cells (oncolysis), leaving normal cells unharmed. Additionally, the presence of the tumour-specific viral infection works as a vaccination triggering the patient's own immune system to mount an anti-cancer response – a treatment known as oncolytic immunotherapy. Virttu's lead oncolytic product SEPREHVIR® has been administered to 102 patients (as at 1st March 2017) with ages ranging from 8 to 84 years and with many different types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma. In these patients, SEPREHVIR can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intratumoural injection, and loco-regional infusion. Virttu's scientific and technical expertise in oncolytic virotherapy has been established over 15 years of research and development activity carried out both in-house and with leading researchers in oncolytic immunotherapy, resulting in many firsts in the field and 68 publications in peer-reviewed journals.

Website:	http://www.virttu.com/
Number of Employees:	N/A
Location:	Leeds
Founded in:	1999
Sector:	Personalized medicine

Walk With Path



Path is developing innovative walking aids for people with mobility issues caused by injury, ageing, and serious diseases such as diabetes, Multiple Sclerosis and Parkinson's Disease. The aim is to reduce the risk of falls, to keep users mobile for longer and increase independence. This has been proven to increase the quality of life for users and reduce direct and indirect costs for health providers. Path products offer the opportunity to increase quality of life and reduce healthcare costs.

Website:	https://www.walkwithpath.com/
Number of Employees:	1-10
Location:	London
Founded in:	2014
Sector:	AgeTech

Xenetic Biosciences



Xenetic Biosciences PLC (formerly Lipoxen PLC) Xenetic is a leading UK-based clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel orphan oncology therapeutics. Their product pipeline includes:

PolyXen™: PolyXen is a patent-protected enabling platform technology designed for protein or peptide therapeutics. It uses the natural polymer polysialic acid (PSA) to prolong a drug's circulating half-life and potentially improve other pharmacological properties. PolyXen has been demonstrated in human clinical trials to confer extended half-life to biotherapeutics such as recombinant human erythropoietin and recombinant Factor VIII (rFVIII). **XBIO-101 (sodium cridanimod):** XBIO-101 is a small-molecule immunomodulator and interferon inducer which, in preliminary studies, has been shown to increase progesterone receptor (PrR) expression in endometrial tissue.

Website:	http://www.xeneticbio.com
Number of Employees:	11-50
Location:	London
Founded in:	2014
Sector:	Preventive medicine
Total Funding Amount:	\$10M

Zio Health is a healthcare platform allowing its users to know molecular health status. The company develops multi-functional electronic devices for measuring, testing and detecting the molecular composition of chemical and biological substances for the presence, absence, or quantity of target molecules.

Their services include analysis of:

- Home Diagnostics (Blood, Urine, Saliva, Breast-milk)
- Point-of-Care Devices for Healthcare institutions
- Remote Medical Testing
- Water Quality Testing
- Food Quality Testing
- Formula Milk Quality Testing

Website:	http://www.zio-health.com
Number of Employees:	11-50
Location:	London
Founded in:	N/A
Sector:	Personalized medicine